Leiter LA, et al. – Researchers assessed the safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab according to diabetes mellitus status using pooled data from 14 trials. Adverse event data were analyzed using descriptive statistics and Cox models. Except for more frequent local injection site reactions with alirocumab, findings showed similar safety for alirocumab vs control treatment, irrespective of diabetes status. Overall, regardless of diabetes status, no increase in hemoglobin A1C or fasting plasma glucose vs control treatment groups was noted.